Serum PCSK9 in polycystic ovary syndrome: Relationship with body mass index and long-term cardiovascular risk
Full Text (PDF)
Sinem Eldem 1 * , Yasemin Taşçı 2 , Rahime Bedir Fındık 3 , Almila Şenat 4 , Aykan Yücel 3
More Detail
1 Department of Obstetrics and Gynecology, Baskent University Konya Education and Research Hospital, Konya, TÜRKİYE2 Department of Obstetrics and Gynecology, Kütahya University of Health Sciences, Kütahya, TÜRKİYE3 Ministry of Health, Ankara City Hospital – Maternity Hospital, Ankara, TÜRKİYE4 İstanbul Taksim Training and Research Hospital, Istanbul, TÜRKİYE* Corresponding Author

Abstract

Objective: To evaluate serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels in polycystic ovary syndrome (PCOS) patients according to body mass index (BMI) and investigate their association with lipid parameters and long-term cardiovascular risk.
Methods: A total of 80 women with PCOS were divided into two groups: normal weight (BMI < 25, n = 40) and overweight/obese (BMI ≥ 25, n = 40). Serum PCSK9 levels were measured via enzyme-linked immunosorbent assay. Lipid profiles, hormone levels, and 30-year Framingham cardiovascular risk scores were analyzed.
Results: Serum PCSK9 levels were significantly higher in the overweight/obese group (27.6 ng/ml) compared to the normal weight group (9.5 ng/ml) (p < 0.05). PCSK9 showed positive correlations with LDL-C, total cholesterol, AMH, and Framingham risk scores. No significant correlation with homeostatic model assessment of insulin resistance or insulin was observed.
Conclusion: Elevated PCSK9 levels in overweight/obese PCOS patients may indicate an increased long-term cardiovascular risk. PCSK9 may serve as a biomarker linking metabolic and reproductive disturbances in PCOS and could be a future therapeutic target.

Keywords

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

J CLIN EXP INVEST, Volume 16, Issue 4, December 2025, Article No: em00851

https://doi.org/10.29333/jcei/17400

Publication date: 09 Nov 2025

Article Views: 13

Article Downloads: 3

Open Access References How to cite this article